- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03231176
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
November 18, 2020 updated by: ASLAN Pharmaceuticals
A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer.
Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER4.
Varlitinib may be beneficial to subjects with cancer by simultaneous inhibition of these receptors.
The purpose of this study is to determine the safety and efficacy of Varlitinib in combination with capecitabine for the treatment of Biliary Tract Cancer.
Eligible patients will receive Varlitinib plus capecitabine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nanjing, China
- No.81 Hospital of The Chinese People's Liberation Army
-
Nanjing, China
- There is 22 sites located in other cities of China, including Nanjing
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 97 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed advanced (unresectable) or metastatic biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and carcinoma of the Ampulla of Vater. This includes clinical diagnosis of biliary tract cancer with histological confirmation of adenocarcinoma.
- Patients who have received and failed one and only one prior line of systemic treatment or advanced or metastatic disease with radiologic evidence of disease progression. This prior line of systemic treatment must also contain gemcitabine
- Patients with radiographically measurable disease based on RECIST v1.1.
- Patients with no evidence of biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below 1.5 x upper level of normal (ULN).
- Patients who are or older than 18 years of age and of or younger than 99 years of age at the time when written informed consent is obtained, and are able to understand and willing to sign the informed consent form.
- Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients with adequate organ and hematological function:
Hematological function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
Renal functions, as follows:
- Estimated glomerular filtration rate or creatinine clearance > 50 mL/min/1.73m2
Hepatic function, as follows:
- Total bilirubin ≤ 1.5 x ULN
- AST and ALT ≤ 5 x ULN
Exclusion Criteria:
- Patients are currently on or have received anti-cancer therapy within the past 3 weeks.
- Patients are currently on or have received radiation or local treatment within the past 3 weeks for the target lesion(s).
- Patients have had major surgical procedures within 14 days prior to study entry.
- Patients have a metastatic brain lesion(s), including asymptomatic and well controlled lesion(s).
- Patients have malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications.
- Patients have any history or presence of clinically significant condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results.
- Patients have any history of other malignancy unless in remission for more than 1 year. (skin carcinoma and carcinoma-in-site of uterine cervix treated with curative intent is not exclusionary).
- Female patients are pregnant or breast feeding.
- Patients who been previously treated with varlitinib or have been previously treated with capecitabine as first line therapy for advanced or metastatic disease. For patients who have previously received capecitabine as radiosensitizer or as part of their adjuvant therapy and their disease has relapsed for more than 6 months after their last dose of capecitabine adjuvant therapy, their capecitabine therapy will not be considered as a line of systemic chemotherapy for metastatic/advanced disease, and thus they can participate in the study.
- Patients have received any investigational drug (or have used an investigational device) within the last 14 days before receiving the first dose of study medication.
- Patients have unresolved or unstable serious toxicity (≥CTCAE 4.03 Grade 2), with the exception of anemia, asthenia, and alopecia, from prior administration of another investigational drug and/or prior cancer treatment.
- Patients have a known positive test for HIV, active hepatitis C, or hepatitis B infection with hepatitis B virus deoxyribonucleic acid exceeding 2000 IU/mL.
- Patients have a known history of drug addiction within last 1 year, on the basis that there could be a higher risk of non-compliance to investigational product.
- Patients need continuous treatment with proton pump inhibitors during the study period.
- Patients have a baseline corrected QT interval QTc> 450 ms or patients with known long QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, an unstable cardiac syndrome in the past 3 months before screening visit, > class 2 New York Heart Association heart failure, > grade 2 Canadian cardiovascular society angina pectoris, or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, or sotalol methadone.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Varlitinib and Capecitabine
|
oral tablets, twice daily
oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Through study duration, estimated 2 years
|
Objective Response Rate defined as the proportion of patients with a confirmed best response of partial response (PR) or complete response (CR), as defined by RECIST v1.1 criteria, based on an Independent Central Review (ICR) of radiological data.
|
Through study duration, estimated 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Through study duration, estimated 2 years
|
Progression Free Survival defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression).
Progression is defined in accordance with the RECIST v1.1 criteria and will be derived using data from the ICR.
|
Through study duration, estimated 2 years
|
Disease Control Rate (DCR)
Time Frame: Through study duration, estimated 2 years
|
Disease control rate is defined as the number (%) of patients with a confirmed response of CR or PR, or with stable disease for a minimum of twelve weeks (- 5 days) from starting treatment.
|
Through study duration, estimated 2 years
|
Duration of Response (DoR)
Time Frame: Through study duration, estimated 2 years
|
The Duration of Response is defined as the time from the date of first documented response until the date of documented disease progression or death in the absence of disease progression, in the subset of patient classified as confirmed responders for the assessment of ORR.
The end of response should coincide with the date of disease progression or death from any cause used for the PFS endpoint.
DoR will be calculated using the ICR data.
|
Through study duration, estimated 2 years
|
Overall Survival (OS)
Time Frame: Through study duration, estimated 2 years
|
Overall Survival is defined as time from the start of treatment until death by any cause.
|
Through study duration, estimated 2 years
|
Safety and tolerability of varlitinib when combined with capecitabine
Time Frame: Through study duration, estimated 2 years
|
Incidence of AEs, categorized in accordance to CTCAE 4.03, and changes from baseline in safety parameters
|
Through study duration, estimated 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 19, 2017
Primary Completion (Actual)
July 5, 2019
Study Completion (Actual)
April 13, 2020
Study Registration Dates
First Submitted
July 25, 2017
First Submitted That Met QC Criteria
July 26, 2017
First Posted (Actual)
July 27, 2017
Study Record Updates
Last Update Posted (Actual)
November 19, 2020
Last Update Submitted That Met QC Criteria
November 18, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASLAN001-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Cancer
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Hospital de Cancer de Barretos - Fundacao Pio XIIUnknown
-
Fudan UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingResectable Biliary Tract CancerChina
-
University of Kansas Medical CenterRecruitingAdvanced Biliary Tract CancerUnited States
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Georgetown UniversityIpsenRecruitingAdvanced Biliary Tract CancerUnited States
-
Seoul National University HospitalBeiGeneActive, not recruitingAdvanced Biliary Tract CancerKorea, Republic of
Clinical Trials on Varlitinib
-
ASLAN PharmaceuticalsCompletedHealthy VolunteersUnited Kingdom
-
National University Hospital, SingaporeUnknownAdvanced/ Metastatic Hepatocellular CarcinomaSingapore
-
ASLAN PharmaceuticalsCompletedCholangiocarcinomaTaiwan, Korea, Republic of, Singapore
-
ASLAN PharmaceuticalsSyneos Health; bioRASI, LLC; CMIC Co, Ltd. JapanCompletedBiliary Tract CancerUnited States, Australia, China, Hong Kong, Hungary, Japan, Korea, Republic of, Poland, Singapore, Spain, Taiwan
-
ASLAN PharmaceuticalsCompletedGastric CancerEstonia, Hong Kong, Korea, Republic of, Lithuania, Malaysia, Singapore, Taiwan, Thailand
-
ASLAN PharmaceuticalsWithdrawnAdvanced or Metastatic Biliary Tract Cancer
-
ASLAN PharmaceuticalsCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract CancerJapan
-
Otsuka America PharmaceuticalCompletedHIV Infections | Sarcoma, KaposiUnited States
-
ASLAN PharmaceuticalsTerminatedBiliary Tract CancerTaiwan, Korea, Republic of, Singapore
-
ASLAN PharmaceuticalsCompletedSolid TumorTaiwan, Hong Kong